Good-Heart6425
Explorer
A New York Times article on chronic inflammation and GLP's: The extensive use of GLP-1s — Ozempic and Zepbound among them — has overturned assumptions about what those answers could be and how quickly we might obtain them. Such drugs seem to lower chronic inflammation across the body to a modest degree, while not hindering the immune system’s capacity to combat infection. For individuals who use GLP-1s for diabetes treatment and to encourage weight loss, some of their chronic conditions have seemed to improve as well.